In adolescents, lower OS and EFS rates than the younger age group are observed. The most appropriate management plan should be made according to the physical and psychosocial needs of patients in this age group.
Adolescence can be defined as a transition period between childhood and adulthood. However, there is not a well-defined age range for this period. World Health Organization defines an individual between 10-19 years as an adolescent. From the oncologic point of view, adolescent cancers are defined as cancers seen between 15-19 years [1] [2] [3] . Lymphomas, leukemias, bone and soft tissue sarcomas, germ cell tumors, and epithelial tumors are the most common cancer types and embryonal tumors of childhood are rare. Despite significant improvement in cancer diagnosis, treatment and survival, similar improvement could not be observed in adolescent cancers. Furthermore, adolescents face many problems while dealing with cancer due to limited awareness about adolescents' requirements in oncology centers specific for children or adults. Less enrollment to clinical trials is another important issue that may be attributed to lower survival rates than other age groups [4] [5] [6] [7] .
Material and Methods
Files of patients between 15-19 years of age diagnosed with cancer between 1970 and 2008 in Hacettepe University, Department of Pediatric Oncology were retrospectively reviewed. Demographic features of patients, cancer types and histopathological subgroups, primary cancer localizations, treatment modalities and non-compliance to treatment were analyzed using descriptive analysis.
All statistical analyses were performed using SPSS statistical software (SPSS Inc, Chicago, IL). Descriptive data are given as percentages. The Kaplan-Meier method was used for survival analysis. Overall survival (OS) was calculated from diagnosis to death or last visit. Event-free survival (EFS) was calculated from diagnosis to death, progression of the disease, or recurrence, whichever came first, or the last visit. Comparison between the patient groups was made by log-rank test. A p value of<0 .05 was considered statistically significant.
Results
Two hundred ninety-three adolescents with cancer were included in the study. There were 189 males and 104 females with a median age of 15 years. Median follow-up time was 8 years and 9 months (range: 1 year-30 years). Lymphomas were the most common tumor in our group. Details of patients are given in Table I The most frequent treatment combination was chemotherapy and radiotherapy. Irregular attendance to chemotherapy schedule and refusing therapy were defined as non-compliance to treatment. Percentage of non-compliance to treatment was 10.9 in whole group and higher in males than females. However, this difference was not statistically significant (p=0.7). Noncompliance to treatment was more common in patients with NHL and osteosarcoma than other tumors. The difference according to non-compliance to treatment between tumor groups was statistically significant (p=0.02). No significant difference was detected according to non-compliance to treatment between early stage or metastatic disease.
Overall survival (OS) was 57.6%, event-free survival (EFS) was 45.7% (median follow-up time: 8 years and 9 months) ( Fig. 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] . In United States, annual cancer incidence between 15-19 years was reported to be 20 in 100,000 10 .
Ad o l e s c e n t c a n c e r s p o r t r a y d i f f e r e n t characteristics compared to childhood and adult cancers 1,2,10,11 . The most common cancer types in this age group are leukemia, lymphoma, bone and soft tissue sarcomas, germ cell tumors, and epithelial tumors. In our study, leukemias were not included to our study and lymphomas, CNS tumors and bone and soft tissue sarcomas were the most common tumors. Germ cell tumors and epithelial tumors were not as frequent as expected. Possibly, this was because these types of adolescent cancers were treated in adult oncology centers. Other studies have also shown cancers like germ cell tumors, carcinomas and malignant melanomas were more likely to be treated in adult centers 12, 13 .
Cancer was reported to be fourth common cause of death among adolescents in United States. Mortality in adolescent cancers arises from four major cancers: sarcomas, leukemia/ lymphomas, malignant CNS tumors and germ cell tumors 11 . Although an increase of 1.5% (per year) in 5-year overall survival in childhood cancers was observed during the last 25 years in America, only 0.9% increase (per year) was reported in adolescent survival rates 14 . One of the main reasons for this consequence is lower clinical trial enrollment among adolescents. Furthermore, controversy still exists on treating an adolescent with cancer whether in a pediatric or adult oncology center 15 . Evidence suggests that better outcome is observed when adolescents with certain types of cancer are treated with pediatric protocols [16] [17] [18] [19] . A new concept of adolescent and young adult (AYA) oncology has emerged in the last decade. This new discipline, involved in patients from15 to 29 (or 39) years of age, was created by cooperative study of pediatric and adult oncologists who use patient-focused multidisciplinary approach in management of cancer treatment 20, 21 . Although this program has been constituted in Europe, North America and Australia, a discipline of AYA oncology is Another possible factor for lower survival rates in adolescents with cancer is noncompliance to treatment. Studies have shown that adolescents have more problems than their younger and older counterparts in terms of compliance 23, 24 . However, lack of precise definition of non-compliance, assessment and measurement can be difficult 25 . Direct evaluation through urine and serum samples and indirect assessment by interviewing with family members or health professionals can be used 24 . Non-compliance can be observed as delayed attending to chemotherapy courses or as not-using recommended medications as well as not attending long-term follow-up 26 . Complicated treatment regimens, unsuitable conditions of hospitals for adolescent's needs, desire of adolescent for independence, insufficient communication between adolescent and health care provider, denial of the disease by adolescent, feeling undefeatable against cancer observed in adolescents may be among factors leading to non-compliance 11 . Our study's retrospective design could not provide a thorough assessment for non-compliance. However, it was observed in one of ten adolescents with cancer. Patients with NHL and osteosarcoma were shown to be more non-compliant to treatment compared to other cancer types.
In conclusion, there are still many issues that need to be addressed in adolescent cancers even in developed countries. First of all, an attempt should be made for increasing the awareness about adolescent cancers in public to prevent the delay in diagnosis. Second, health care providers should be informed about characteristics of adolescent period in order to cope well with adolescents. Third, a suitable treatment center that meets the special needs of this age group provided for optimal treatment. Finally, enrollment to clinical trials of adolescents with cancer should be encouraged for a better outcome. Furthermore, the concept of AYA oncology discipline should be constituted even in developing countries.
